Please provide your email address to receive an email when new articles are posted on . Denosumab as a first-line osteoporosis therapy is linked to lower fracture risks than alendronate among ...
Denosumab may reduce fracture risk, but increase cardiovascular risks in patients on dialysis. Denosumab may reduce fracture risk better than oral bisphosphonates for treatment of osteoporosis in ...
Findings from a phase 3 trial showed denosumab-dssb had comparable efficacy, safety, immunogenicity, PK and PD to Prolia in patients with postmenopausal osteoporosis. Ospomyv is approved to treat ...
Please provide your email address to receive an email when new articles are posted on . The denosumab and placebo groups had an estimated difference of 8.9 in the Ghent University Scoring System at 24 ...
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OSPOMYV™ (denosumab ...
Science and society collaboration is essential for scientific progress, especially in the health and biomedical fields where basic researchers, clinicians and patients are involved, as shown by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results